Much about the behavior of the Zika virus is unknown because it is unknown how much circulation of Zika there has been in the past in areas of the world outside the Americas.
Researchers are scrambling to develop a Zika vaccine.
The race to develop a vaccine against the Zika virus is fueled by the potential profit.
Epidemiology and Burden of Disease
New and Emerging Vaccines
Preclinical and Clinical Trials
Delivery Vaccine Safety
Vaccine efficacy may be improved by exploiting cross-reactive antibodies.
Researchers have discovered an immune antibody that can evolve to neutralize a wide array of influenza virus strains.
Researchers tested vaccines against Ebola and H1N1 flu that were effective in lab mice, and have also tested a RNA vaccine for Zika that had successful results.
Of the vaccines under development, only two projects involve major manufacturers.